How should I evaluate and manage soft, foul‑smelling stools in a patient with ulcerative colitis who does not have diarrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evaluation and Management of Soft, Foul-Smelling Stools in UC Without Diarrhea

You should first measure fecal calprotectin, CRP, or fecal lactoferrin to determine if active inflammation is present, as soft stools with altered odor can represent mild UC activity even without frank diarrhea. 1

Initial Diagnostic Approach

Your symptom pattern—soft, fluffy, malodorous stools without true diarrhea—represents a mild symptom presentation that requires objective assessment before treatment decisions. The 2023 AGA guidelines are explicit about this scenario.

Step 1: Biomarker Testing

Obtain fecal calprotectin, fecal lactoferrin, or serum CRP to distinguish between:

  • Active inflammation requiring treatment escalation
  • Non-inflammatory symptoms (functional overlay, bile acid malabsorption, SIBO, dietary factors)

Critical thresholds 1:

  • Fecal calprotectin >150 mg/g suggests active inflammation
  • Elevated fecal lactoferrin or CRP similarly indicates inflammation
  • Normal biomarkers (<150 mg/g calprotectin) make moderate-to-severe inflammation unlikely

Step 2: Interpretation and Next Steps

If biomarkers are elevated (calprotectin >150 mg/g):

  • Proceed to endoscopic assessment rather than empirically escalating therapy 1
  • This confirms whether mucosal inflammation is present and guides treatment decisions
  • Rule out Clostridioides difficile and other enteric pathogens, as biomarkers can be elevated from non-IBD causes 1

If biomarkers are normal:

  • Endoscopic assessment is still recommended for mild symptoms with normal biomarkers 1
  • However, if you prefer to avoid immediate endoscopy, repeat biomarkers in 3-6 months is a reasonable alternative 1
  • Consider alternative causes (see below)

Alternative Pathophysiologic Mechanisms

Since your stools are soft and malodorous but not liquid diarrhea, consider these non-inflammatory causes 2:

  1. Bile acid malabsorption - particularly if you have ileal disease or prior resection
  2. Small intestinal bacterial overgrowth (SIBO) - can cause soft, foul-smelling stools
  3. Carbohydrate intolerance (lactose, fructose) - produces gas, bloating, and soft stools
  4. Dietary factors - high FODMAP foods can cause similar symptoms

Stool consistency matters: Recent evidence shows that Bristol Stool Form Scale type 6-7 (mushy/liquid) is independently associated with active disease, even in endoscopic remission 3. Your "soft fluffy" description likely corresponds to Bristol type 5-6, which warrants investigation.

Management Algorithm

If Active Inflammation is Confirmed:

For mild UC activity 4, 5:

  • Start or optimize oral 5-ASA 2-4 g/day combined with topical 5-ASA (enemas/suppositories)
  • If no response in 2-4 weeks, add prednisolone 40 mg daily, tapering over 6-8 weeks
  • If you've required ≥2 steroid courses in the past year, consider treatment escalation to thiopurines, anti-TNF, vedolizumab, or JAK inhibitors 4

If No Active Inflammation (Functional Symptoms):

Symptomatic management 2:

  • Bile acid sequestrants (cholestyramine) for chronic loose stools in quiescent UC
  • Low FODMAP diet trial with dietitian supervision
  • Probiotics may be considered
  • Avoid opiates for any associated discomfort

Critical Pitfalls to Avoid

  1. Don't assume symptoms = inflammation: Up to 34% of patients with bowel urgency have endoscopic remission 3. Soft stools can persist despite mucosal healing.

  2. Don't empirically escalate therapy without objective evidence: The AGA explicitly recommends against this for mild symptoms 1

  3. Don't ignore infection: Always test for C. difficile and enteric pathogens when biomarkers are elevated 1

  4. Don't overlook functional overlap: Histologic inflammation and stool form are independent predictors of symptoms, even with endoscopic remission 3

Monitoring Strategy

If you proceed with biomarker monitoring rather than immediate endoscopy:

  • Repeat fecal calprotectin in 3-6 months 1
  • If persistently elevated on repeat testing, endoscopy becomes necessary
  • Serial monitoring allows anticipatory management and may catch subclinical flares 2

The key principle: Combine symptoms with objective biomarkers rather than relying on symptoms alone to guide treatment decisions 1. Your unusual stool pattern warrants investigation, not assumption.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.